WallStSmart

Lifecore Biomedical Inc. (LFCR)vsTakeda Pharmaceutical Co Ltd ADR (TAK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Takeda Pharmaceutical Co Ltd ADR generates 3480161% more annual revenue ($4.51T vs $129.47M). TAK leads profitability with a 4.3% profit margin vs -23.8%. TAK appears more attractively valued with a PEG of 0.40. TAK earns a higher WallStSmart Score of 57/100 (C).

LFCR

Avoid

28

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: -0.73

TAK

Buy

57

out of 100

Grade: C

Growth: 6.7Profit: 4.0Value: 6.3Quality: 5.0
Piotroski: 4/9Altman Z: 1.18

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LFCR1 strengths · Avg: 10.0/10
Debt/EquityHealth
-10.0410/10

Conservative balance sheet, low leverage

TAK3 strengths · Avg: 10.0/10
PEG RatioValuation
0.4010/10

Growing faster than its price suggests

Price/BookValuation
1.0x10/10

Reasonable price relative to book value

EPS GrowthGrowth
330.2%10/10

Earnings expanding 330.2% YoY

Areas to Watch

LFCR4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$211.18M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.662/10

Expensive relative to growth rate

TAK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
3.9%4/10

3.9% revenue growth

Return on EquityProfitability
2.5%3/10

ROE of 2.5% — below average capital efficiency

Profit MarginProfitability
4.3%3/10

4.3% margin — thin

Operating MarginProfitability
3.1%3/10

Operating margin of 3.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : LFCR

The strongest argument for LFCR centers on Debt/Equity.

Bull Case : TAK

The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.

Bear Case : LFCR

The primary concerns for LFCR are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : TAK

The primary concerns for TAK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 42.5x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

LFCR profiles as a turnaround stock while TAK is a value play — different risk/reward profiles.

LFCR carries more volatility with a beta of 1.07 — expect wider price swings.

TAK is growing revenue faster at 3.9% — sustainability is the question.

LFCR generates stronger free cash flow (4M), providing more financial flexibility.

Bottom Line

TAK scores higher overall (57/100 vs 28/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lifecore Biomedical Inc.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Lifecore Biomedical, Inc., is an integrated contract development and manufacturing organization in the United States and internationally. The company is headquartered in Santa Maria, California.

Takeda Pharmaceutical Co Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?